Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2020201267 - IDENTIFICATION OF PAN-GAMMA SECRETASE INHIBITOR (PAN-GSI) THERANOSTIC RESPONSE SIGNATURES FOR CANCERS

Publication Number WO/2020/201267
Publication Date 08.10.2020
International Application No. PCT/EP2020/059091
International Filing Date 31.03.2020
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
Applicants
  • KØBENHAVNS UNIVERSITET [DK]/[DK]
Inventors
  • ANDERSEN, Jesper, Bøje
  • O'ROURKE, Colm
Agents
  • INSPICOS P/S
Priority Data
19166515.701.04.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IDENTIFICATION OF PAN-GAMMA SECRETASE INHIBITOR (PAN-GSI) THERANOSTIC RESPONSE SIGNATURES FOR CANCERS
(FR) IDENTIFICATION DE SIGNATURES DE RÉPONSE THÉRANOSTIQUE DE PAN-GAMMA SECRÉTASE (PAN-GSI) POUR DES CANCERS
Abstract
(EN)
The present invention relates to gene signatures and gene expression profiles which may provide predictive molecular tools for clinical applications. The invention also relates to methods of predicting the sensitivity of cancers in a human subject to specific anticancer drugs, particularly gamma secretase inhibitor. The invention further relates to the use of such gene signatures as cancer biomarkers in the treatment and in patient selection for optimizing drug response and putative selection of combination therapy to improve outcome assisting the medical practitioners and patients with more effective and individualized anticancer treatments.
(FR)
La présente invention concerne des signatures géniques et des profils d'expression génique qui peuvent fournir des outils moléculaires prédictifs pour des applications cliniques. L'invention concerne également des procédés de prédiction de la sensibilité de cancers chez un sujet humain à des médicaments anticancéreux spécifiques, en particulier un inhibiteur de gamma-sécrétase. L'invention concerne en outre l'utilisation de telles signatures géniques en tant que biomarqueurs du cancer dans le traitement et dans la sélection de patient pour optimiser la réponse médicamenteuse et la sélection putatives d'une polythérapie permettant d'obtenir de meilleurs résultats cliniques pour les praticiens et apporter aux patients des traitements anticancéreux plus efficaces et individualisés.
Latest bibliographic data on file with the International Bureau